EPS growth is an important number as it indicates the future prospects of Biofrontera AG. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 54.20 % over the last twelve months. The higher the EPS growth rate, the higher the value that is added to shareholders and a good reflection on the performance of the management at Biofrontera AG.
Biofrontera AG is in the healthcare sector and is in the biotechnology industry. The company CEO is Hermann Lubbert. Biofrontera AG is a pharmaceutical company in the United Kingdom. It develops drugs and cosmetic products for the treatment of skin related diseases.
Previous Intraday Performance:
The BFRA shares had a previous change of 0.21% which opened at 12.55 and closed at 12.63. It moved to an intraday high of 12.65 and a low of 12.61.
SeekingAlpha: Biofrontera: Ameluz – The Key Future Value Driver
Historical Performance:
Over the last five trading days, BFRA shares returned 1.20% and in the past 30 trading days it returned -5.04%. Over three months, it changed -12.90%. In one year it has changed 3.69% and within that year its 52-week high was 17.98 and its 52-week low was 11.25. BFRA stock is 12.27% above its 52 Week Low.
Our calculations result in a 200 day moving average of 13.65 and a 50 day moving average of 12.99. Right now, BFRA stock is trading -7.47% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: Biofrontera: Ameluz – The Key Future Value Driver
Liquidity:
The company has a market cap of $281.5m with 22.3m shares outstanding and a float of 22.3m shares. Trading volume was 1,708 shares and has experienced an average volume of 2,381 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Biofrontera AG was -0.96 which ended on 31st of December 2017.
Below was the last reported quarterly earnings per share:
09-30-2018: -0.23
06-30-2018: -0.23
03-31-2018: -0.20
12-31-2017: -0.09
Base on our calculations, the intrinsic value per share is 8.22, which means it might overvalued by -53.72%
Indicators Also to Watch:
Based on the latest filings, there is 2.20% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 0.73
SeekingAlpha: Notable earnings before Tuesday’s open
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -169.56%, return on assets is -57.95%, profit margin is -71.42%, price-to-sales is 14.60 and price-to-book is 19.06.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: BFRA, Biofrontera AG, Biotechnology, Healthcare
